Last reviewed · How we verify
Bupivacaine-epinephrine
Bupivacaine blocks sodium channels in nerve cell membranes to produce local anesthesia, while epinephrine causes vasoconstriction to prolong anesthetic duration and reduce systemic toxicity.
Bupivacaine blocks sodium channels in nerve cell membranes to produce local anesthesia, while epinephrine causes vasoconstriction to prolong anesthetic duration and reduce systemic toxicity. Used for Local and regional anesthesia for surgical procedures, Infiltration anesthesia, Nerve blocks.
At a glance
| Generic name | Bupivacaine-epinephrine |
|---|---|
| Also known as | Bupivacaine 0.5% with adrenaline vasoconstrictor 1: 200,000, Marcain-adrenalin (combination drug), Marketing Authorisation Holder: AstraZeneca, Marketing Authorisation number: 10213, Exparel |
| Sponsor | Lumbini Medical College |
| Drug class | Local anesthetic with vasopressor |
| Target | Voltage-gated sodium channels; alpha-1 and beta-2 adrenergic receptors |
| Modality | Small molecule |
| Therapeutic area | Anesthesia |
| Phase | FDA-approved |
Mechanism of action
Bupivacaine is a long-acting amide local anesthetic that reversibly inhibits sodium influx into nerve fibers, preventing depolarization and action potential propagation. Epinephrine is a sympathomimetic agent added to the formulation that causes vasoconstriction of local blood vessels, which slows systemic absorption of bupivacaine, extends the duration of anesthesia, and reduces the risk of systemic toxicity.
Approved indications
- Local and regional anesthesia for surgical procedures
- Infiltration anesthesia
- Nerve blocks
- Epidural anesthesia
Common side effects
- Transient paresthesia
- Headache
- Back pain
- Hypotension
- Tachycardia
- Nausea
- Systemic toxicity (CNS or cardiac)
Key clinical trials
- The Efficiency of Periarticular Multimodal Drug Injection in Pain Management Following Primary Unilateral TKA (NA)
- Mid-transverse Process Combined With Erector Spinae Block Versus Paravertebral Plane Block (NA)
- Cervicothoracic Sympathetic Block Evaluation for Post COVID Condition (PHASE4)
- Postop Pain Management in Pituitary Tumour Patients (PHASE4)
- Multifidus Plane Block Versus Caudal Block for Hypospadias (NA)
- Sacral ESPB vs. PENG Block for Hip Hemiarthroplasty Analgesia (NA)
- Phase 3 Herniorrhaphy Study for Postoperative Analgesia (EPOCH 2) (PHASE3)
- Total Knee Arthroplasty Infiltration Study for Postoperative Analgesia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bupivacaine-epinephrine CI brief — competitive landscape report
- Bupivacaine-epinephrine updates RSS · CI watch RSS
- Lumbini Medical College portfolio CI